Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizanlizumab rollover study in sickle cell disease
2024-510734-41-00Phase 4Authorised
- Sponsor
- Novartis
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 4, open-label, single-arm trial of crizanlizumab in sickle cell disease (SCD), sponsored by Novartis. Planned start Jun 2021; status: authorised.
02
Drugs
crizanlizumab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2024-510734-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510734-41-00.